Abstract
The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIG) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have